Botha MH - Search Results

1

Botha MH, Rajaram S, Karunaratne K. Botha MH, et al. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:137-142. doi: 10.1002/ijgo.12621. Int J Gynaecol Obstet. 2018. PMID: 30306590

2

A nontoxic concentration of cisplatin induces autophagy in cervical cancer: selective cancer cell death with autophagy inhibition as an adjuvant treatment.

Leisching G, Loos B, Botha M, Engelbrecht AM. Leisching G, et al. Int J Gynecol Cancer. 2015 Mar;25(3):380-8. doi: 10.1097/IGC.0000000000000365. Int J Gynecol Cancer. 2015. PMID: 25695544

3

Introducing human papillomavirus vaccines into the health system in South Africa.

Botha MH, Dochez C. Botha MH, et al. Vaccine. 2012 Sep 7;30 Suppl 3:C28-34. doi: 10.1016/j.vaccine.2012.03.032. Vaccine. 2012. PMID: 22939017 Review.

4

The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.

Leisching GR, Loos B, Botha MH, Engelbrecht AM. Leisching GR, et al. Among authors: botha mh. Toxicology. 2015 Sep 1;335:72-8. doi: 10.1016/j.tox.2015.07.010. Epub 2015 Jul 19. Toxicology. 2015. PMID: 26201060

5

The Vaccine and Cervical Cancer Screen (VACCS) project: Linking cervical cancer screening to HPV vaccination in the South-West District of Tshwane, Gauteng, South Africa.

Snyman LC, Dreyer G, Botha MH, van der Merwe FH, Becker PJ. Snyman LC, et al. Among authors: botha mh. S Afr Med J. 2015 Jan 6;105(2):115-20. doi: 10.7196/samj.8418. S Afr Med J. 2015. PMID: 26242529

6

Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.

Leisching G, Loos B, Botha M, Engelbrecht AM. Leisching G, et al. J Transl Med. 2015 Oct 16;13:328. doi: 10.1186/s12967-015-0689-4. J Transl Med. 2015. PMID: 26474854 Free PMC article.

7

Women's experiences with cervical cancer screening in a colposcopy referral clinic in Cape Town, South Africa: a qualitative analysis.

Momberg M, Botha MH, Van der Merwe FH, Moodley J. Momberg M, et al. Among authors: botha mh. BMJ Open. 2017 Feb 17;7(2):e013914. doi: 10.1136/bmjopen-2016-013914. BMJ Open. 2017. PMID: 28213603 Free PMC article.

8

Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort.

Simonds HM, Botha MH, Neugut AI, Van Der Merwe FH, Jacobson JS. Simonds HM, et al. Among authors: botha mh. Gynecol Oncol. 2018 Nov;151(2):215-220. doi: 10.1016/j.ygyno.2018.08.038. Epub 2018 Sep 5. Gynecol Oncol. 2018. PMID: 30194006

9

Exploring the feasibility of using mobile phones to improve the management of clients with cervical cancer precursor lesions.

Moodley J, Constant D, Botha MH, van der Merwe FH, Edwards A, Momberg M. Moodley J, et al. Among authors: botha mh. BMC Womens Health. 2019 Jan 7;19(1):2. doi: 10.1186/s12905-018-0702-1. BMC Womens Health. 2019. PMID: 30616579 Free PMC article.

10

HIV status does not have an impact on positron emission tomography-computed tomography (PET-CT) findings or radiotherapy treatment recommendations in patients with locally advanced cervical cancer.

Simonds H, Botha MH, Ellmann A, Warwick J, Doruyter A, Neugut AI, Van Der Merwe H, Jacobson JS. Simonds H, et al. Among authors: botha mh. Int J Gynecol Cancer. 2019 Oct;29(8):1252-1257. doi: 10.1136/ijgc-2019-000641. Epub 2019 Aug 13. Int J Gynecol Cancer. 2019. PMID: 31413068

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page